PCSK9 and diabetes mellitus: In patients with metabolic disturbances, the most optimal use is pitavastatin (that does not increase new onset diabetes or even has a potential to reduce the risk), ezetimibe, bempedoic acid, and a PCSK9 inhibitor/modulator.